PEDIATRICS Vol. 82 No. 2 August 1988, pp. 283-284
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MCMILLAN, J. A.
Right arrow Articles by WEINER, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MCMILLAN, J. A.
Right arrow Articles by WEINER, L. B.

Ribavirin Use Questioned

JULIA A. MCMILLAN MD1 and LEONARD B. WEINER MD1

1 Department of Pediatrics, Division of Infectious Diseases, University of Pittsburgh School of Medicine Pittsburgh, PA 15213

In Reply.—

The concerns of Dashefsky et al regarding the validity of the studies that led to the FDA approval of aerosolized ribavirin for the treatment of patients with respiratory syncytial virus infection are well described in their critical review of those studies.1 We agree that none of those studies provided the kind of conclusive quantification of ribavirin's efficacy that should preclude further placebocontrolled trials. Nonetheless, ribavirin is on the market, and physicians who care for young infants hospitalized with respiratory syncytial virus infection must decide whether and when it should be used.